Artificial intelligence (AI) isn't the only industry with explosive growth potential.
Investor's Business Daily on MSN
The gene-editing news that sent beleaguered Intellia Therapeutics stock up
Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.
In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds. Genetic manipulation – or gene editing – is a concept that describes altering the genetic ...
The stock has lost significant market value since that debacle. While it's not clear that nex-z was responsible, it's also ...
CRISPR technology may soon lead to major stock growth in genomics. CRISPR therapies target diseases with genetic editing either inside or outside the body. Beam, CRISPR Therapeutics, Caribou, and ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...
Beam Therapeutics is one of the few biotechs that has shown immense potential in the gene therapy space. The company’s proprietary base-editing technology potentially enables the development of a ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results